SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)
1. SCY-247 shows in vitro activity against resistant C. auris strains. 2. Presentations at TIMM-12 highlight SCY-247's antifungal capabilities. 3. Phase 1 SAD/MAD data for SCY-247 expected in Q3 2025. 4. In vivo efficacy of SCY-247 demonstrated against C. auris in mice. 5. SCY-247 exhibits no cross-resistance to existing echinocandins.